CA2498233A1 — Clear ophthalmic solution comprising latanoprost as active ingredient
Assigned to Santen Pharmaceutical Co Ltd · Expires 2004-03-18 · 22y expired
What this patent protects
It is intended to provide an improved formulation of latanoprost eye drops. Namely, transparent eye drops containing latanoprost as the active ingredien t and benzalkonium chloride as a preservative wherein clouding due to a composition change is prevented by using at least one m…
USPTO Abstract
It is intended to provide an improved formulation of latanoprost eye drops. Namely, transparent eye drops containing latanoprost as the active ingredien t and benzalkonium chloride as a preservative wherein clouding due to a composition change is prevented by using at least one means selected from th e following means 1) to 3). 1) A means of adding a surfactant; 2) a means of using benzalkonium chloride represented by the formula ~C6H5CH2N(CH3)2R~Cl (wherein R represents C12 alkyl)as the benzalkonium chloride; and 3) a means of adding a nonionic isotonic agent as an isotonic agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.